- Home
- VLY vs INAB Comparison
VLY vs INAB Comparison
Compare VLY & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLY
- INAB
- Stock Information
- Founded
- VLY 1927
- INAB 2016
- Country
- VLY United States
- INAB United States
- Employees
- VLY N/A
- INAB N/A
- Industry
- VLY Major Banks
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- VLY Finance
- INAB Health Care
- Exchange
- VLY Nasdaq
- INAB Nasdaq
- Market Cap
- VLY 5.2B
- INAB 9.1M
- IPO Year
- VLY N/A
- INAB 2021
- Fundamental
- Price
- VLY $11.00
- INAB $2.03
- Analyst Decision
- VLY Buy
- INAB Strong Buy
- Analyst Count
- VLY 12
- INAB 2
- Target Price
- VLY $11.75
- INAB $108.00
- AVG Volume (30 Days)
- VLY 7.6M
- INAB 45.9K
- Earning Date
- VLY 10-23-2025
- INAB 11-11-2025
- Dividend Yield
- VLY 4.10%
- INAB N/A
- EPS Growth
- VLY 9.10
- INAB N/A
- EPS
- VLY 0.78
- INAB N/A
- Revenue
- VLY $1,603,358,000.00
- INAB N/A
- Revenue This Year
- VLY $33.98
- INAB N/A
- Revenue Next Year
- VLY $8.90
- INAB N/A
- P/E Ratio
- VLY $13.77
- INAB N/A
- Revenue Growth
- VLY N/A
- INAB N/A
- 52 Week Low
- VLY $7.48
- INAB $1.91
- 52 Week High
- VLY $11.10
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- VLY 71.95
- INAB 41.71
- Support Level
- VLY $10.46
- INAB $1.98
- Resistance Level
- VLY $10.94
- INAB $2.20
- Average True Range (ATR)
- VLY 0.24
- INAB 0.11
- MACD
- VLY -0.01
- INAB -0.01
- Stochastic Oscillator
- VLY 94.79
- INAB 33.33
About VLY Valley National Bancorp
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.